✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Astrazeneca Pharma India Ltd.

ASTRAZEN

Market Cap
₹20,957 Cr.
P/E
111.76

Astrazeneca Pharma India Ltd.

  • Astrazeneca Pharma
  • Pfizer
  • Eris Lifesciences
  • TJI Pharma - Small Cap

FAQs on Astrazeneca Pharma India Ltd. Shareprice

Astrazeneca Pharma has given better returns compared to its competitors.
Astrazeneca Pharma has grown at ~28.54% over the last 8yrs while peers have grown at a median rate of 7.52%

Astrazeneca Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Astrazeneca Pharma is 111, while 3 year average PE is 122.
Also latest EV/EBITDA of Astrazeneca Pharma is 78.27 while 3yr average is 74.16.

View FAQ's On Business

Growth Table

  • Astrazeneca Pharma India Ltd.
  • Pfizer
  • Eris Lifesciences

Balance Sheet

  • Astrazeneca Pharma India Ltd.
  • Pfizer
  • Eris Lifesciences

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Astrazeneca Pharma India Ltd.
  • Pfizer
  • Eris Lifesciences

Cash Flow

  • Astrazeneca Pharma India Ltd.
  • Pfizer
  • Eris Lifesciences

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Astrazeneca Pharma India Ltd.
  • Pfizer
  • Eris Lifesciences

Quarterly Results

  • Astrazeneca Pharma India Ltd.
  • Pfizer
  • Eris Lifesciences

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Astrazeneca Pharma India Ltd. Financials

Balance sheet of Astrazeneca Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Astrazeneca Pharma is increasing.
Latest net debt of Astrazeneca Pharma is -₹448.62 Crs as of Mar-26.
This is greater than Mar-25 when it was -₹1,073.4 Crs.

The profit is oscillating.
The profit of Astrazeneca Pharma is ₹188 Crs for TTM, ₹116 Crs for Mar 2025 and ₹162 Crs for Mar 2024.

The company seems to pay a good stable dividend.
Astrazeneca Pharma latest dividend payout ratio is 69.12% and 3yr average dividend payout ratio is 48.85%

Companies resources are allocated to majorly unproductive assets like Inventory

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech